Upgrades/Downgrades
Updated: 13-Jul-26 09:45 ET
| Upgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Verra Mobility | VRRM | JP Morgan | Underweight » Neutral | $6 | |
| Solstice Advance Materials | SOLS | UBS | Neutral » Buy | $78 | |
| Shopify | SHOP | Jefferies | Hold » Buy | $160 | |
| Saia | SAIA | BofA Securities | Neutral » Buy | $502 | |
| Pembina Pipeline | PBA | Wells Fargo | Underweight » Overweight | ||
| NIO | NIO | Goldman | Neutral » Buy | $7 | |
| Keysight | KEYS | Morgan Stanley | Equal-Weight » Overweight | $400 | |
| Humana | HUM | Wells Fargo | Equal Weight » Overweight | $502 | |
| Deckers Outdoor | DECK | Jefferies | Hold » Buy | $130 | |
| Casey's General | CASY | Northcoast | Neutral » Buy | $950 | |
| Capital One | COF | HSBC Securities | Hold » Buy | $229 | |
| Biogen | BIIB | Truist | Hold » Buy | $235 | |
| BeOne Medicines | ONC | Jefferies | Hold » Buy | $380 | |
| American Express | AXP | JP Morgan | Neutral » Overweight | $400 | |
|
|
|||||
| Downgrades | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Sun Life | SLF | Evercore ISI | Outperform » In-line | ||
| Sezzle | SEZL | Keefe Bruyette | Outperform » Mkt Perform | $190 | |
| ResMed | RMD | Citigroup | Buy » Neutral | $235 | |
| Porch Group | PRCH | Keefe Bruyette | Outperform » Mkt Perform | $16.25 | |
| Papa John's | PZZA | BofA Securities | Neutral » Underperform | $34 | |
| Best Buy | BBY | Loop Capital | Buy » Hold | $82 | |
| AstraZeneca | AZN | HSBC Securities | Buy » Hold | ||
|
|
|||||
| Coverage Initiated | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| Stoke Therapeutics | STOK | Goldman | Buy | $44 | |
| SiteOne Landscape Supply | SITE | KeyBanc Capital Markets | Overweight | $145 | |
| Praxis Precision Medicines | PRAX | Goldman | Buy | $447 | |
| MSC Industrial | MSM | Rothschild & Co Redburn | Buy | $155 | |
| MDU Resources | MDU | Wells Fargo | Overweight | $25 | |
| Kardigan | KARD | JP Morgan | Overweight | $51 | |
| Kardigan | KARD | TD Cowen | Buy | $46 | |
| Kardigan | KARD | Jefferies | Buy | $40 | |
| Honeywell Aerospace | HONA | Evercore ISI | In-line | $250 | |
| First Carolina Financial Services | FCBM | Raymond James | Outperform | $15 | |
| Fastenal | FAST | Rothschild & Co Redburn | Buy | $55 | |
| Equillium | EQ | Piper Sandler | Overweight | ||
| Deep Fission | FISN | The Benchmark Company | Buy | $20 | |
| Costco | COST | RBC Capital Mkts | Sector Perform | $1000 | |
| Candel Therapeutics | CADL | Stifel | Buy | $22 | |
| BrightSpring Health Services | BTSG | Guggenheim | Buy | $81 | |
| Atmos Energy | ATO | Wells Fargo | Overweight | $200 | |
| Apyx Medical | APYX | H.C. Wainwright | Buy | $7 | |
| Whirlpool | WHR | BNP Paribas Exane | Neutral | $43 | |
| Liftoff Mobile | LFTO | Tigress Financial | Buy | $39 | |
| Nervgen Pharma | NGEN | Leerink Partners | Outperform | $10 | |
| Kardigan | KARD | Leerink Partners | Outperform | $37 | |
| Whitehawk Therapeutics | WHWK | Leerink Partners | Outperform | $9 | |
| West Pharm | WST | BNP Paribas Exane | Outperform | $447 | |
| Glass House Brands | GLAS | Lake Street | Buy | $17 | |
| Park Aerospace | PKE | Needham | Buy | $43 | |
| Spruce Biosciences | SPRB | B. Riley Securities | Buy | $160 | |
|
|
|||||
| Coverage Resumed | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| York Space Systems | YSS | Jefferies | Buy | $32 | |
| NovoCure | NVCR | JP Morgan | Neutral | $17 | |
| Legend Biotech | LEGN | JP Morgan | Neutral | $35 | |
| Denali Therapeutics | DNLI | JP Morgan | Overweight | $29 | |
| BioCryst Pharma | BCRX | JP Morgan | Neutral | $12 | |
| Alkermes Plc | ALKS | JP Morgan | Neutral | $60 | |
|
|
|||||
| Coverage Reiterated/Price Tgt Changed* | |||||
| Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
| MasTec | MTZ | TD Cowen | Buy | $445 » $470 | |
| Netflix | NFLX | Oppenheimer | Outperform | $120 » $100 | |
|
|
|||||
| (a) Brokerage firm initiating coverage participated in underwriting the recent IPO. |
| (b) Brokerage firm resumes coverage. |
| (c) Brokerage firm participated in the secondary offering. |
| * This list of reiterations/target changes is not comprehensive. |